obesity drug news today glp-1 october 2025 Outlook for obesity in 2025: more than a transition year The outlook for obesity from

GLP-1 patches vs

10.1016/S0140-6736(23)01289-8 36 KapoorI.SarvepalliS

Gynaecologia et perinatologia: journal for gynaecology, perinatology, reproductive medicine and ultrasonic diagnostics

12 As to whether GLP-1 drugs were associated with changes in DME, there is still not yet enough conclusive evidence

The suppression of the NLRP3 inflammasome and the promotion of an M2 phenotype in macrophages (Section 2.3) directly translates into more stable atherosclerotic plaques with a reduced inflammatory burden (Section 2.1) [29,43]

Food intake, particularly ingestion of carbohydrate-rich food, increases GLP-1 secretion, which promotes post-prandial insulin secretion, -cell proliferation, and glucose homeostasis, contributing to reducing glucose levels and aiding weight loss